Is Innoviva, Inc. (NASDAQ:INVA) a buy in 2026?
Yes, on balance. The Compass leans toward accumulating Innoviva, Inc. at current levels.
A GSK royalty cheque funding a hospital antibiotic portfolio the market refuses to value. Hidden compounder at 3.6x earnings.
Where INVA is headed
Most investors who glance at Innoviva see a slowly fading royalty stream from GSK's Trelegy and Anoro franchises, slap a low single-digit multiple on it, and move on. That's the lazy read. The interesting version of Innoviva in 2028 looks nothing like a royalty wind-down. It looks like a profitable hospital anti-infective specialist with a back-catalogue of cash-printing inhaled respiratory royalties bolted on, run by an activist-aligned board that thinks like capital allocators rather than drug developers.
Read the full Compass Direction on INVA
The complete destination call, the overlooked angle, milestones, and bull, base, and bear price scenarios (around $22.61).
See the full INVA analysisGet calls like this, free
Join the Alexandria e-letter for forward-looking verdicts, earnings intelligence, and the contrarian reads the crowd misses. Twice a week, no noise.
Free forever. Unsubscribe anytime. We never share your email.
Frequently asked questions
Is Innoviva, Inc. (NASDAQ:INVA) a buy in 2026?
Yes, on balance. The Compass leans toward accumulating Innoviva, Inc. at current levels. A GSK royalty cheque funding a hospital antibiotic portfolio the market refuses to value. Hidden compounder at 3.6x earnings.
What is INVA's Compass Score?
Innoviva, Inc. scores 79/100 on Alexandria's Compass, placing it in the "True North" tier. Scores blend eight factors and update weekly.
What is the price target for INVA?
Alexandria's full Compass Direction includes bull, base, and bear price scenarios with the valuation math behind each. Read the full breakdown on the INVA page.
Compass verdicts are AI-generated, forward-looking editorial research from publicly available data, not investment advice or a recommendation regarding any security. Scores and verdicts update as the data changes.